CarcinoQuant AB
ABActiveOrg 5591684518Förändringens Gata 10, 431 53 MölndalResearch and experimental development on natural sciences and engineering· NACE 7210Est. 2018 · 8 years old5-9 employees
Loading company…
Overview
CarcinoQuant AB is a Swedish AB based in Mölndal, operating in the Research and experimental development on natural sciences and engineering sector. Incorporated in 2018, the company reported revenue of SEK 0 in its latest annual filing.
Revenue 2025
0M SEK
EBITDA margin
—
Net profit 2025
-0.1M SEK
-437% vs 2024
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
95.9 %
Very strongAmong the 20% highest rated companies in the industry
20212025
Liquidity ratioCurrent assets ÷ Short-term debt
15.0×
Very strongAmong the 20% highest rated companies in the industry
20212025
Return on assets (ROA)Net profit ÷ Total assets × 100
-1.0 %
WeakAmong the 30% lowest rated companies in the industry
20212025
EBITDA — year on year
SEK thousandsKey figures
Annual report 2025| Revenue | 0M SEK | — |
| EBITDA | -0.1M SEK | -3799% |
| Net profit | -0.1M SEK | -437% |
| Total assets | 6.4M SEK | +13221% |
| Equity | 6.2M SEK | +14143% |
| Employees | — | — |
Company information
Legal name
CarcinoQuant AB
Org number
5591684518
Legal form
Aktiebolag
Founded
20 August 2018 · 8 years
Share capital
SEK 50,000
Employees
5-9
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska utveckla och sälja metoder för läkemedelsutveckling och diagnostik inom sjuk- och hälsovårdsbranschen.
(no translation available)
Contact
Address
Förändringens Gata 10, 431 53 Mölndal
Email
wenzel.nisshagen@carcinoquant.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2025), CarcinoQuant AB reported revenue of SEK 0. The figures on this page draw on 5 annual filings covering 2021 to 2025. The bottom line showed a net loss of SEK 61.9k.
At the end of 2025, equity financed 95.9% of the balance sheet, and current assets covered short-term debt 15 times.
Financials
Revenue
SEKEBITDA
SEK thousandsIncome statement
SEK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | -0 | -0 | -0 | -0 | — |
| EBITDA | -64 | -2 | -7 | -1 | -3 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -64 | -2 | -7 | -1 | -3 |
| Net financials | 2 | 0 | -0 | 0 | — |
| Profit before tax | -62 | 18 | -7 | -1 | -3 |
| Tax | -0 | -0 | -0 | -0 | -0 |
| Net profit | -62 | 18 | -7 | -1 | -3 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
SEK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 6,448 | 48 | 30 | 37 | 39 |
| Equity | 6,182 | 43 | 25 | 32 | 34 |
| Long-term debt | 250 | 0 | 0 | 0 | 0 |
| Short-term debt | 17 | 5 | 5 | 5 | 5 |
| Total debt | 267 | 5 | 5 | 5 | 5 |
Financial ratios
5-year trendEBITDA margin
<−999 %
20212025
Equity ratio
95.9 %
Very strongAmong the 20% highest rated companies in the industry
20212025
Return on equity
-1.0 %
WeakAmong the 30% lowest rated companies in the industry
20212025
Net profit margin
<−999 %
20212025
Asset turnover
0.00×
Very weakAmong the 10% lowest rated companies in the industry
20212025
Debt / equity
0.04×
Very strongAmong the 20% highest rated companies in the industry
20212025
Sector performance
23 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Return on equity (ROE)Weak
Among the 30% lowest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Weak
Among the 30% lowest rated companies in the industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Weak
Among the 30% lowest rated companies in the industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Weak
Among the 40% lowest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Gross marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Capacity ratioNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current ratioVery strong
Among the 20% highest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioVery strong
Among the 20% highest rated companies in the industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioVery strong
Among the 20% highest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityVery strong
Among the 10% highest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalWeak
Among the 30% lowest rated companies in the industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioAverage
Around the average of companies in the same industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioVery strong
Among the 20% highest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioVery strong
Among the 20% highest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityVery strong
Among the 20% highest rated companies in the industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityVery strong
Among the 20% highest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtVery weak
Among the 20% lowest rated companies in the industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtWeak
Among the 30% lowest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageVery weak
Among the 10% lowest rated companies in the industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtVery strong
Among the 20% highest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginWeak
Among the 30% lowest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Asset turnoverVery weak
Among the 10% lowest rated companies in the industry
Revenue relative to total assets — the ability to generate revenue from the asset base.
Equity to contributed capitalVery strong
Among the 10% highest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityVery strong
Among the 10% highest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtVery weak
Among the 10% lowest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Inventory turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Annual reports & filings
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
EH Chief Executive Officer | Chief Executive Officer | 2026 |
Former (3)
JE | Audit | 2020 – 2021 |
MF Chief Auditor | Chief Auditor | 2022 – 2025 |
ST Chief Auditor | Chief Auditor | 2021 – 2022 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (6) | ||
KJ Board of Directors | Board of Directors | 2026 |
TS Board of Directors | Board of Directors | 2026 |
KH Board of Directors | Board of Directors | 2026 |
NL Chairman | Chairman | 2026 |
BH Board of Directors | Board of Directors | 2026 |
SW Board of Directors | Board of Directors | 2020 |
Former (3)
LO Board of Directors | Board of Directors | 2020 – 2026 |
LA Board of Directors | Board of Directors | 2020 – 2026 |
CE Board of Directors | Board of Directors | 2020 – 2026 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
Antaros Holding AB
CarcinoQuant AB Board network connections
Board members of CarcinoQuant AB also hold positions in 555 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Magnus Fjellman | Chief Auditor | 298 companiesMany roles |
| John Erik Andreas Österlund | Audit | 109 companiesMany roles |
| Sven Tiberiu Cristea | Chief Auditor | 72 companiesMany roles |
| Lars Anders Strigén | Board of Directors | 34 companiesMany roles |
| Tor Simon Angeldorff | Board of Directors | 15 companiesMany roles |
| Sven Wenzel Johannes Hulthe | Board of Directors | 9 companiesMany roles |
| Lars Olof Mikael Johansson | Board of Directors | 5 companies |
| Erik Helge Wenzel Nisshagen | Chief Executive Officer | 4 companies |
| Bo Henning Lennart Johnson | Board of Directors | 4 companies |
| Karl Joel Kullberg | Board of Directors | 2 companies |
| Karl Håkan Ahlström | Board of Directors | 1 company |
| Christina Elisabeth Abrahamsson | Board of Directors | 1 company |
| Nils Lennart Thurfjell | Chairman | 1 company |
Frequently asked questions
What is the Org number of CarcinoQuant AB?
CarcinoQuant AB is registered with Bolagsverket / SCB under Org 5591684518.
Who is the CEO of CarcinoQuant AB?
Erik Helge Wenzel Nisshagen is the CEO of CarcinoQuant AB, in role since 2026.
Who is the chairman of CarcinoQuant AB?
Nils Lennart Thurfjell chairs the board of CarcinoQuant AB, in role since 2026.
Where is CarcinoQuant AB headquartered?
CarcinoQuant AB's registered address is Förändringens Gata 10.